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Rapid and transient oxygen 
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Epigenetic deregulation, such as the reduction of histone acetylation levels, is thought to be causally 
linked to various maladies associated with aging. Consequently, histone deacetylase inhibitors are 
suggested to serve as epigenetic therapy by increasing histone acetylation. However, previous work 
suggests that many non-histone proteins, including metabolic enzymes, are also acetylated and that 
post transitional modifications may impact their activity. Furthermore, deacetylase inhibitors were 
recently shown to impact the acetylation of a variety of proteins. By utilizing a novel technique to 
measure oxygen consumption rate from whole living tissue, we demonstrate that treatment of whole 
living fly heads by the HDAC/KDAC inhibitors sodium butyrate and Trichostatin A, induces a rapid and 
transient increase of oxygen consumption rate. In addition, our study indicates that the rate increase 
is markedly attenuated in midlife fly head tissue. Overall, our data suggest that HDAC/KDAC inhibitors 
may induce enhanced mitochondrial activity in a rapid manner. This observed metabolic boost 
provides further, but novel evidence, that treating various maladies with deacetylase inhibitors may be 
beneficial.
Epigenetic deregulation is associated with the onset and progression of many diseases1–3. For example, changes 
in lysine acetylation in histones, an important modification that alters chromatin structure and affects transcrip-
tion activation, have been causally related with cancer, neurodegeneration, psychiatric disorders, various other 
maladies, and aging2,4–9. In many of these diseases, including cancer4 and cognitive decline6,10,11, lower histone 
acetylation and transcription deregulation are proposed as causal mechanisms; however, during early phases of 
aging, higher histone acetylation are observed8,12. As such, much effort has been aimed towards finding epigenetic 
treatments that increase histone acetylation levels.
Histone deacetylation is mediated by nuclear histone deacetylases (HDACs)13. Notably, many molecules that 
inhibit the activity of HDAC’s have been examined14,15. Among them are broad-spectrum classical HDAC inhib-
itors like Sodium Butyrate (SB), Trichostatin A (TSA), Veronistat (SAHA), and others. Treatment with these 
HDAC inhibitors increased histone acetylation and had beneficial impacts on cancer and neurodegeneration 
treatments, improved cognitive function, and others5,10,11,14–20.
Recent technological improvements in mass spectrometry analysis have revealed the presence of lysine acetyl-
ation in hundreds of non-histone proteins13,21–24. Many of these acetylated sites are located in mitochondria and 
can be deacetylated by class III deacetylases, the sirtuins, which are not sensitive to classical HDAC inhibitors 
such as SB, TSA and SAHA13,25. Nonetheless, numerous acetylated proteins, including transcription factors and 
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metabolic enzymes involved in glycolysis and acetyl-CoA metabolism, are located in the cytoplasm and nucleus. 
Previously, it was shown that various HDACs, located in the cytoplasm and the nucleus, mediate the acetylation 
of various proteins13. As such, they should be referred to as lysine (K) deacetylases or KDACs. Importantly, acetyl-
ation of these non-mitochondrial metabolic enzymes impacts their activity8,22,26,27. KDAC inhibitors, such as SB 
and TSA, that can target KDACs in the cytoplasm could potentially increase the acetylation of metabolic enzymes 
and ultimately affect metabolic rates25,28,29.
It was previously shown in Drosophila that chronic reduction of KDAC1 (Rpd3) by RNAi treatment results 
in increased citrate synthase activity, a marker for mitochondrial activity30. In addition, chronic treatment with 
SB caused increased oxygen consumption in mice31. However, the relative effect of chronic KDAC inhibition on 
the acetylation of metabolic enzymes in contrast to complex transcriptional changes, mediated by altered histone 
acetylation that affects the abundance of metabolic enzymes, remains to be elucidated. Importantly, it is unclear 
whether acute and rapid KDACi treatment, which may not involve transcription, impacts metabolic activity.
We recently demonstrated that administration of SB and TSA to a whole Drosophila head caused increased 
oxygen consumption rate (OCR) after five cycles (Approximately half an hour) of measurement28. To gain further 
insight into the dynamic impact of acute KDAC inhibition on metabolism, we focused on characterizing the 
time-depended OCR changes that occur following KDAC inhibition in young and midlife male fly heads.
Results
Opposing trends in oxygen consumption rate in isolated mitochondria and whole head tis-
sue. Measuring oxygen consumption from isolated mitochondria is a common readout for cellular meta-
bolic activity32. However, recent studies suggest that isolated mitochondria lack the complexity of whole cell 
tissue12,33–35. To address this problem, we implemented a novel technique to measure oxygen consumption rate 
from whole fly head (see methods). This technique enables the steady measurement of OCR in living male fly 
heads for at least 20 measurements (Fig. 1A and Supplementary Table 1).
We next compared the OCR of one week (young) and four week (midlife) old male fly heads28. Using a sin-
gle measurement, we previously showed that OCR in midlife fly head was increased compared to the young 
group28. Interestingly, analysis of three consecutive measurements from whole tissue exhibited increased OCR in 
midlife tissue (Fig. 1B), but isolated mitochondria from midlife fly head, which lack cellular/tissue complexity33,35, 
exhibited decreased levels of OCR (Fig. 1C). While the reason for these conflicting results remain unclear and 
discussed elsewhere12, it is possible that older mitochondria are more fragile and thus break down more easily 
during mitochondrial isolation34,35. This emphasizes the importance of measuring OCR from whole tissue, which 
more closely reflects physiological complexity.
Sodium butyrate induced a rapid and transient OCR increase in young fly heads. To evaluate the 
impact of sodium butyrate (SB) on OCR over time, we treated whole living head tissue with SB. Our data indicate 
that SB induced a significant and rapid increase in OCR after 4 measurements (Supplementary Table 1) following 
the drug treatment compared to the vehicle group (Fig. 2A and B). Induction of OCR peaked at 5 measurements 
and subsided after a total of 10 measurements following the addition of the drug (Supplementary Table 1) in the 
SB-treated group. A second addition of SB induced a second but lesser and more transient increase in OCR in the 
young fly head tissue. Inhibition of complex I of the respiratory chain by rotenone caused a significant reduction 
of OCR in whole fly tissue (Fig. 2C). Nonetheless, the addition of SB to rotenone treated heads caused increased 
OCR, supporting the hypothesis that SB is likely to stimulate OCR increase via alternative targets (Fig. 2C).
Figure 1. A novel method to measure dynamic oxygen consumption rate of whole living fly head tissue. (A) 
Young male fly head tissue display a stable oxygen consumption rate (OCR) over 20 consecutive measurements. 
(B) Three consecutive measurements of OCR in whole fly tissue show an increased OCR in midlife whole heads 
compared to young whole head. N = 20 young and 22 midlife. (C) Isolated mitochondria from midlife fly heads 
indicate reduced OCR compared to isolated mitochondria from young fly heads. N = 12 per group. (*P < 0.05, 
**P < 0.01, ***P < 0.001). Error bars indicate the S.E.M. in all the graphs.
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Sodium butyrate induced a modest OCR increased in midlife fly heads. Sodium butyrate and 
other KDACi are currently promoted to treat various age-associated maladies5,14,15,36. While the beneficial impact 
of KDACi in treating age-related maladies is hypothesized to be mediated by histone acetylation and transcrip-
tional changes, we recently demonstrated that SB causes a very rapid increase in oxygen consumption in midlife 
fly head after five cycles (Approximately half an hour) of measurement28. Similarly to young fly heads, SB induces 
a rapid increase of OCR as early as after 3 measurements following the addition of the drug (Fig. 3A). In contrast, 
the amplitude of the OCR increase is reduced and shorter compared to the young group (Fig. 2A). Likewise, a 
second consecutive injection of SB results in a mild and short OCR increase (Fig. 3A). Similarly to the young 
group, inhibition of the respiratory chain by rotenone caused a significant reduction of OCR in midlife fly heads 
(Fig. 3B). The addition of SB to rotenone treated heads also increased OCR in the midlife group (Fig. 3B).
TSA induced a rapid and transient increase in OCR in whole young fly heads. Although sodium 
butyrate is considered a HDAC/KDAC inhibitor, it is also a metabolite. Indeed, several cell types within the colon 
utilize butyrate as a metabolite for energy production15,37,38. In fact, previous studies indicated that the addition 
of butyrate causes increased oxygen consumption in colonic cell types39,40. While this phenomenon may be due 
to the cells’ proximity to butyrate produced by local colonic bacteria15,37, we tested a second KDAC inhibitor to 
corroborate our original hypothesis/strengthen our results.
We previously demonstrated that similarly to SB, TSA induces OCR increase after five cycles (Approximately 
half an hour) of measurement in whole young fly head28. Interestingly, compared to SB, TSA induced a faster 
increase in OCR, evident already in the first measurement following the addition of the drug (Fig. 4A,B and 
Supplementary Table 1). Of note, while TSA induced a more rapid response, the overall increase in OCR was less 
compared to SB treatment. Furthermore, a second injection of TSA after 70 minutes resulted in a second but more 
transient increase in OCR (Fig. 4B).
Discussion
In this study, we used a novel approach to measure oxygen consumption of whole living tissue. The clear advan-
tage is that this technique allows our determination in near-physiologic conditions, unlike classically isolated 
mitochondrial measurements33. For instance, in whole tissue, mitochondria cross talk with many other cellular 
processes that may influence mitochondrial activity. Furthermore, in a tissue cell-to cell communications still 
exist within a new tissue, a factor that may further influence metabolic rates12. Also, during mitochondria isola-
tion, many posttranslational modifications (PTM’s) may be lost, resulting in metabolic change artifacts12; it is less 
likely that PTM’s are lost if the examined tissue is still alive.
This is important as our results suggest that PTM’s such as acetylation are of significant importance28. SB, 
and in particular TSA, induce rapid increases in OCR. Such quick OCR increase is likely to precede and be 
independent of new gene transcription following protein translation41, and therefore not directly mediated by 
Figure 2. Sodium butyrate induces a dynamic and rapid increase in oxygen consumption rate in young fly 
whole head tissue. (A) Representative oxygen level changes showing decreased oxygen levels due to oxygen head 
consumption in control and SB treated samples. In SB treated fly heads, the oxygen drops to low levels and the 
OCR decreases at the last ‘ticks’. Therefore, we use the FIXED algorithm (See Methods). Each measurement (two 
minutes) consists of 10 sub-measurements referred to as a ‘tick’. The dashed line indicates the addition of SB. (B) 
Quantification of (A). Sodium butyrate (SB) induces a rapid and transient increase in oxygen consumption in 
the heads of young flies. A second injection after 10 measurements following the first injection results in a lower 
and shorter increase of OCR. Data was normalized to the measurement prior to addition of SB. The dashed 
lines indicate the addition of SB. N = 9 vehicle and 8 SB. (C) The addition of rotenone, a complex I inhibitor, 
significantly reduced OCR in whole fly head tissue. However, the addition of sodium butyrate induces increased 
OCR in the rotenone treated samples. The dashed line indicates the addition of rotenone or rotenone + SB. 
N = 9 per group. (*P < 0.05, **P < 0.01, ***P < 0.001). Error bars indicate the S.E.M. in all the graphs.
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Figure 3. Sodium butyrate causes a lower and shorter increase in midlife fly whole head tissue. (A) Sodium 
butyrate (SB) induces a slight increase in oxygen consumption in the heads of midlife flies compared to the 
younger group. A second injection after 10 measurements following the first injection results in a lower and 
shorter increase of OCR. Data was normalized to the measurement prior to addition of SB. The dashed lines 
indicate the addition of SB. N = 9 per group. (B) The addition of rotenone significantly reduced the OCR in 
whole fly head tissue of midlife. Similarly to the results in Fig. 2C, the addition of sodium butyrate induces 
an increase in OCR in the rotenone treated samples. The dashed line indicates the addition of rotenone or 
rotenone + SB. N = 9 per group. (*P < 0.05, **P < 0.01) Error bars indicate the S.E.M. in all the graphs.
Figure 4. TSA causes a dynamic and very rapid increase in oxygen consumption rate in young fly whole head 
tissue. (A) Representative oxygen head consumption in control and TSA treated samples. Similarly to the results 
in Fig. 2A, in TSA treated fly heads, the oxygen drops to low levels and the OCR decreases at the last ‘ticks’. We 
use the FIXED algorithm to model the results (See Methods). The dashed line indicates the addition of TSA. (B) 
Quantification of (A). TSA induces a very rapid and transient increase in oxygen consumption in the heads of 
young flies. A second injection after 10 measurements following the first injection results in a shorter increase 
of OCR but not lower. Data was normalized to the measurement prior to addition of TSA. The dashed lines 
indicate the addition of TSA. N = 5 vehicle and 6 TSA. (*P < 0.05, **P < 0.01). Error bars indicate the S.E.M. in 
all the graphs.
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histone acetylation. Indeed, our data suggests that SB and TSA impact OCR via non-histone protein acetylation, 
a dynamic process that can occur within the time-frame we observe23,28, but happens too quickly for results 
due to transcriptional changes41. The hypothesis that KDAC inhibitors impact metabolic activity independently 
from altering histone acetylation is valuable. It suggests that rather than epigenetic–mediated therapy, KDACi 
causes a metabolic “boost” that is crucial for KDACi-characterized benefits. For example, KDACi may cause an 
increase in mitochondrial activity in age-related disorders such as neurodegeneration characterized by reduced 
metabolic activity36,42. Furthermore, in cancer cells that exhibit altered metabolic activity, KDACi–induced met-
abolic changes could therapeutically target harmful cancer cells in a specific manner5,14. Further work is required 
to elucidate whether KDACi–induced metabolic increase is beneficial for various conditions affected by altered 
metabolic activity.
How do KDACi induce rapidly increased OCR? One possibility is that KDAC inhibition results from increased 
acetylation of cytosolic enzymes belonging to the glycolytic process26. If the result of this increased acetylation 
is increased glycolysis and mitochondrial pyruvate/acetyl-CoA levels and hence increase mitochondrial protein 
acetylation, it may cause a downstream increase of mitochondrial activity. Also, if the KDACi cause altered activ-
ity of enzymes, which shift the ADP/ATP balance or other relevant metabolites and cofactors, that may cause a 
change in the rate of oxidative phosphorylation.
It is important to note that while the activity of KDACs, with the exception of sirtuins, is believed to primarily 
occur in the nucleus and cytoplasm13, previous work had shown that several KDACs are present in the mitochon-
dria during Xenopus development43. Furthermore, previous results in prostate cancer epithelial cells showed that 
KDAC7 is localized to the mitochondria44. Therefore, we cannot rule out the possibility that KDACi can inhibit 
KDACs that directly impact the acetylation of mitochondrial proteins. More work is needed to identify KDACi 
targets that result in increased OCR.
KDACi treatment has less impact on midlife fly head tissue. Since the OCR is already elevated in midlife, it 
is possible that the metabolic range is resistant to further increases12. We speculate that higher levels of protein 
acetylation in midlife limit further increase by KDACi28. Reaching this threshold level of OCR may explain why a 
second injection of KDACi to head tissue produces a weak OCR increase. Alternatively, it is possible the KDACi 
elicit a negative feedback that results in inhibition of OCR increase upon the second injection.
Large amounts of data suggest that epigenetic deregulation is linked with diseases and age-associated dis-
orders, and manipulating histone acetylation can serve as KDACi-mediated therapy2,8,9. In fact, the combined 
KDACi impact on metabolism and epigenetic regulation may be crucial for successful treatment8,16. While KDAC 
inhibitors can cause increased levels of histone acetylation directly by inhibiting histone deacetylases, alternative 
mechanisms should be considered. First, KDACi can alter the acetylation and consequent activity of transcription 
factors that remodel DNA–histone interactions13,24,25. Second, increasing data demonstrate a relationship between 
metabolic activity and epigenetics28,45–50. For example, acetyl-CoA metabolism that produces the precursor for 
acetylation reactions significantly regulate levels of histone acetylation8,28,45. Our results indicate that KDACi 
can impact metabolic activity and support the hypothesis that KDACi indirectly increases histone acetylation by 
increasing the metabolic activity, resulting in higher levels of acetyl-CoA.
In summary, our results suggest a novel ability of KDAC inhibitors to induce a rapid and transient OCR 
increase. Our data support the concept that alternative, non-epigenetic mechanisms can be impacted by KDACi 
mediated therapy. Indeed, while histone acetylation was considered the main mechanism through which thera-
peutic benefits occur for various maladies, we now propose that modulating metabolism, protein acetylation, and 
metabolic-epigenetic relationships underlie the mechanism of successful KDACi-mediated therapy.
Materials and Methods
Flies. Flies (Canton) of mixed population of males and females were housed in 12 hour dark/light cycles at 
25 °C, in 60% humidity and with free access to food as recently described, with an addition of yeast powder28. The 
food was changed every 2–3 days.
Oxygen consumption assay from isolated mitochondria. Isolated mitochondria were extracted from 
16 heads of one week or four week old male flies according to the manufacturer’s protocol (Seahorse/Agilent)32 
and their oxygen consumption rate measured by the XF-96 well plate (Seahorse Agilent). Activation of the res-
piratory chain was initiated by ADP addition to the medium.
Oxygen consumption assay in whole tissue. Oxygen consumption rate from whole tissue was meas-
ured as previously described28. In brief, male flies were anesthetized on an ice cold metal platform and their heads 
were removed by forceps. 16 fly heads were placed on a net (Seahorse/Agilent), carefully centered, and then 
inserted into a well (16 heads/well). Each well was filled with fresh Seahorse buffer (700 µl) containing freshly 
made 2.5% glucose. During preparation, the cart bridge was calibrated according to the manufacturer’s instruc-
tion and calibrated at 31–33 °C. Oxygen consumption measurements were collected in cycles of three minutes 
mixing, two minutes delaying phase, and a two minute measurement at 31–33 °C (Supplementary Table 1). While 
each cycle is calculated a total of 7 minutes, an extra of approximately half a minute of delay between mixing 
-delaying phase – measuring is added (Supplementary Table 1). Each two-minute measurement was divided into 
10 sub-measurements referred to as “ticks” (See Figs 2A and 4A).
For direct injections, 77 µL and 85 µL (first and second injections, respectively) of fresh assay buffer were 
injected. A stock solution of fresh sodium butyrate (Sigma) of 150 mM was dissolved in the assay buffer before 
injection and pH adjusted, to a final concentration of 15 mM. Rotenone (Sigma) was dissolved in DMSO and a 
stock solution of 50 µM was prepared in the assay buffer to a final concentration of 5 µM. TSA (Sigma) was dis-
solved in DMSO and a stock solution of 10 µM was prepared in the assay buffer to a final concentration of 1 µM.
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Oxygen consumption rate (OCR) was calculated with AKOS algorithm as previously described51. However, 
the oxygen levels decreased too rapidly and became too low (Anoxia) in the SB and TSA treated samples, resulting 
in a considerable decrease in OCR in the final sub-measurements (ticks) due to lower oxygen concentration (See 
Figs 2A and 4A). Therefore, the OCR in SB/TSA experiments was calculated with”FIXED” algorithm (Seahorse 
website).
Statistical analysis. All data were tested positive for normal distribution. Data in Fig. 1 were analyzed with 
unpaired two‐tailed Student’s t‐test. For time course effects of drug treatments, the unpaired two‐tailed Student’s 
t‐test was performed and resulting p-values were corrected for multiple comparisons.
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